BDBM220364 US9290488, B20a(ii)

SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O

InChI Key InChIKey=YSMGRXHMHZXHMK-PPGQYDOQSA-N

Data  4 KI  3 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 220364   

TargetOpioid growth factor receptor-like protein 1(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataKi:  7.44nM ΔG°:  -11.1kcal/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataKi:  154nM ΔG°:  -9.29kcal/molepH: 7.4 T: 2°CAssay Description:Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataKi:  159nM ΔG°:  -9.27kcal/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataKi:  3.92E+3nM ΔG°:  -7.37kcal/molepH: 7.4 T: 2°CAssay Description:Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOpioid growth factor receptor-like protein 1(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataEC50:  51.1nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataEC50:  363nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent